Neifeld Ref: UTEX0010UPCT-US

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Paul INT APP. NO: 10/581,295 FILED: 3/29/2004

GAU:

EXAMINER:

FOR: Lupus Antibodies for Passive Immunotherapy of HIV/AIDS

PTO CONFIRMATION NO. 3691

37 CFR 1.97 IN	NFORMATION D	SCLOSURE STATEMENT	
ASSISTANT COMMISSIONER FOR PATENTS ALEXANDRIA, VA 22313	s		
SIR: Applicant(s) wish to disclose the followin	g information.		
REFERENCES			
being submitted herewith or, were sub-	mitted in the parent or gran	he attached PTO-1449. Copies of the listed refer dparent application, where required, as were eithe nent portions of any non-English language referen	er statements
A check is attached in the amount requ	uired under 37 CFR §1.17(	p).	
RELATED CASES  Attached is a list of applicant's pendin A copy of the patent(s) is attached alor  A check is attached in the amount requ	ng with PTO 1449.	natent(s) which may be related to the present appli	cation.
CERTIFICATION			
		statement was cited in a communication from a fooths prior to the filing of this statement.	oreign patent
office in a counterpart foreign applicat	tion or, to the knowledge o	tatement was cited in a communication from a for f the undersigned, having made reasonable inquiry months prior to the filing of this statement.	
PETITION			
Applicant(s) hereby request considerate required under 37 CFR §1.17(p).	tion of the attached informa	tion. A check is attached in the amount of the Pet	tition fee
DEPOSIT ACCOUNT			incd
		rith and for which no check is enclosed herewith,	or credit any
31518 PATENT TRADEMARK OFFICE		Respectfully submitted,	
	02/06/2007	/RobertHahl#33,893/	_
	Date	Robert Hahl Registration No. 33,893	_

G

1.17

iany

NEIFELD IP LAW REFERENCE FORM	NEIFELD REF: UTEX0010UPCT-US	APPLICATION NO: 10/581,295
LIST OF REFERENCES CITED BY THE APPLICANT	FIRST NAMED INVENTOR: Paul	
(Rev: 5/14/2003)	FILING DATE: 3/29/2004	GROUP ART UNIT:

#### LISTING OF UNITED STATES PATENTS - U series

EXAMINER INITIALS	REFERENCE NUMBER (U SERIES)	PATENT NUMBER	ISSUE DATE	NAME OF PATENTEE OR APPLICANT	PAGE/LINE AND FIGURE/ELEMENT OF RELEVANT MATERIAL AND/OR IDENTIFICATION OF PRIORITY APPLICATION IN WHICH REFERENCE IS CITED
	U-001	5,445,960	8/29/1995	Masuho et al.	
	U-002	5,695,927	12/9/1997	Masuho et al.	
	U-003	5,783,670	7/21/1998	Masuho et al.	
	U-004	5,807,715	9/15/1998	Morrison et al.	
	U-005	5,811,238	9/22/1998	Stemmer et al.	
	U-006	5,952,462	9/14/1999	Powell et al.	
	U-007	6,156,541	12/5/2000	Paul et al.	
	U-008	6,235,714	5/22/2001	Paul et al.	
	U-009	6,406,863	6/18/2002	Zhu et al.	
	U-010	6,407,213	6/18/2002	Carter et al.	
-					
Date:			Examiner's Sig	mature.	

## LISTING OF UNITED STATES PUBLISHED APPLICATIONS - P Series

EXAMINER INITIALS	REFERENCE NUMBER (P SERIES)	PUBLICATION NUMBER	PUBLICATION DATE	NAME OF PATENTEE OR APPLICANT	PAGEALINE AND FIGURE/ELEMENT OF RELEVANT MATERIAL AND/OR IDENTIFICATION OF PRIORITY APPLICATION IN WHICH REFERENCE CITED
	P-001	US 2003/00782 03	4/24/2003	Paul et al.	
	ļ		ļ		
			ļ		
<del> </del>					
			<u> </u>		
				ļ	
			<u> </u>		
			ļ		
	ļ				
	I		1		

# LISTING OF FOREIGN AND INTERNATIONAL PATENT DOCUMENTS - F Series

EXAMINER INITIALS	REFERENCE NUMBER (F SERIES)	PUBLICATION NUMBER	PUBLICATION DATE	COUNTR Y OR REGION	PAGE/LINE AND FIGURE/ELEMENT OF RELEVANT MATERIAL	ENGLISH LANGUAGE TRANSLATION ATTACHED? (YES OR NO) AND/OR IDENTIFICATION OF PRIORITY APPLICATION IN WHICH REFERENCE IS CITED
						——————————————————————————————————————
				<u> </u>		
				<u> </u>		
				<u> </u>		***************************************
		-				
		,				
			w			
						***
						·
						,
Date:			Examiner's Sig	nature:		

## LISTING OF NON PATENT LITERATURE - O Series

		PAILNI	LITERATURE - U Series	
EXAMINER INITIALS	REFERENCE NUMBER (O Series)	PUBLICATION DATE	INCLUDE IN SEQUENCE: Name of first author (in CAPITAL LETTERS), Title in quotation marks, name of publication, date or publication, page numbers, publisher, city of publication, and country of publication	ENGLISH LANGUAGE TRANSLATION ATTACHED? (YES OR NO) AND/OR OR IDENTIFICATION OF PRIORITY APPLICATION IN WHICH REFERENCE IS CITED
	O-001		International Search report, PCT/US04/09399, mailed June 1, 2005.	
	O-002		Written Opinion of the International Searching Authority, PCT/US04/09399, mailed June 1, 2005.	
	O-003		International Search report, PCT/US04/09662, mailed June 28, 2006.	
	O-004		Written Opinion of the International Searching Authority PCT/US04/09662, mailed June 28, 2006.	
	O-005	3/28/2003	Paul et al., "Specific HIV gp 120- cleaving antibodies induced by covalently reactive analog of gp 120. J. Biol. Chem. 30 May 2003, Vol. 278, No. 22, pages 20429-20435.	
	O-006		Nishiyama et al., "Antibodies to the Superantigenic Site of HIV-1 gp 120: Hydrolytic and Binding Aactivities of the Light Chain Subunit" submitted with application US 60/857,764, filed November 9, 2006.	-
	O-007		"Induction of antibodies to the gp120 superantigenic site by administration of protein A" submitted with application US 60/857,764, filed November 9, 2006.	
	O-008		Planque et al., "Naturally Occurring Catalytic IgAs: Protective Anti-HIV Mediators?" submitted with application US 60/857,764, filed November 9, 2006.	
	O-009		Planque et al., "Ontogeny of Proteolytic Immunity: IgM Serine Proteases" submitted with application US 60/534,689, filed January 8, 2004.	
	O-010		Karle et al., "Selective IgM-Catalyzed Hydrolysis of HIV gp120: An innate defense against gp120?" submitted with application US 60/534,689, filed January 8, 2004.	

O-4	011	12/15/200	Nishiyama et al., "Toward selective covalent inactivation of pathogenic antibodies" J. Biol. Chem. 27 February 2004, Vol. 279, No. 9, pages 7877-7883.	
0-	-012		Planque et al., "Broadly Distributed Chemical Reactivity of Natural Antibodies Expressed in Coordination with Specific Antigen Binding Activity" submitted with application in US 60/457,293, filed March 26, 2003.	
0-	013		Karle et al., "HIV-1 Neutralizing Antibody Fragments to a Conserved Envelope Determinant from Lupus Libraries" submitted with application in US 60/457,570, filed March 27, 2003.	
O-f	-014	1/2000	Paul et al., "Natural catalytic immunity is not restricted to autoantigenetic substrates: Identification of a human immunodeficiency virus gp 120-cleaving antibody light chain" Appl. Biochem Biotechnol. Jan-Mar 2000, Vol. 83, No, 1-3, pages 71-82.	
O-1	015	11/7/1994	Pinto et al. "Panel of anti-gp 120 monoclonal antibodies reacts with same nuclear proteins in uninfected cells as those recognized by autoantibodies from patients with systemic lulus erythematosus" Aids Res. And Hum Retroviruses, 1994, Vol. 10, pages 823-828.	
0.4	016	11/6/1996	Fraziano et al., "Epitope specificity of anti-HIV antibodies in human and murine autoimmune diseases" Aids Research and Human Retroviruses, 1996, Vol. 12, No. 6, pages 491-496.	
0-4	017	1995	Root-Bernstein, "Preliminary evidence for idiotype-antidiotype immune complexes cross-reactive with Lymphocyte antigenss in AIDS and lupus" Medical Hypotheses (1995) 44, 20-27.	

O-018	2002	Taguchi et al. "A mechanism-based probe for gp 120-hydrolyzing antibodies" Bioorg. Med. Chem. Lett. 2002, Vol. 12, pages 3167-3170.	

Examiner's Signature:
Examiner's Signature:

Printed: May 14, 2003 (3:24pm)
Y:\Clients\University of Texas\UTEX0010\UTEX0010UPCT-US\Drafts\ReferenceCitation\_2-2-2007.wpd